Table 2.
Bisphosphonates: potency, administration and main indications
| Type of BPs | Potency | Administration | Main Indications |
|---|---|---|---|
|
NNBPs | |||
| Etidronate |
1 |
Oral |
Osteoporosis, Paget’s disease of bone |
| Clodronate |
10 |
Oral/ Intravenous |
Osteoporosis, Paget’s disease of bone |
| Tiludronate |
10 |
Oral |
Paget’s disease of bone |
|
NBPs | |||
| Pamidronate |
100 |
Intravenous |
Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, Paget’s disease of bone |
| Alendonate |
500 |
Oral |
Osteoporosis, Paget's disease of bone |
| Ibandronate |
1000 |
Oral, Intravenous |
Osteoporosis |
| Risedronate |
2000 |
Oral, Intravenous |
Osteoporosis, Paget’s disease of bone, osteolytic lesions of multiple myeloma, hypercalcemia of malignancy |
| Zoledronate | 10000 | Intravenous | Osteolytic lesions of multiple myeloma and metastases from solid tumors, hypercalcemia of malignancy |